CRISPR Test Accelerates Mycobacterial Diagnosis

Nanodroplet technology identifies multiple mycobacterial species within hours, offering a faster route to targeted treatment decisions

October 21, 2026
2 min

The Pathologist

At a Glance

Category	Detail
Condition	Mycobacterial infections, including tuberculosis and nontuberculous mycobacterial infections
Key Mechanisms	CANDI combines broad-range DNA amplification with species-specific CRISPR recognition in fluorescently labeled nanodroplets to identify multiple mycobacterial species.
Target Population	People undergoing evaluation for suspected mycobacterial infection, including suspected mixed infections or immunocompromised patients.
Care Setting	Diagnostic laboratories evaluating mycobacterial specimens; routine clinical implementation has not yet been established.

Key Highlights

CANDI can identify 15 clinically relevant mycobacterial species within hours.
The platform identified mixtures containing up to five species, including closely related organisms in the M. abscessus and M. avium complexes.
Clinical testing showed high agreement with culture-based identification and detected some organisms missed by conventional methods.
Molecular detection alone cannot distinguish active infection from colonization; results require interpretation alongside clinical findings.
Manual droplet preparation, chip loading, and fluorescence microscopy remain practical barriers; further automation and validation are needed.

Guideline-Based Recommendations

Diagnosis

CANDI uses broad-range amplification followed by species-specific CRISPR reactions to identify mycobacteria.
The article states that molecular detection alone cannot distinguish active infection from colonization and should be interpreted alongside clinical findings.

Management

Monitoring & Follow-up

Risks

Conventional culture-based identification can take days to weeks.
The current CANDI workflow requires manual droplet preparation, chip loading, and fluorescence microscopy, potentially limiting throughput and standardization.
The authors state that further automation and validation are needed before routine clinical implementation.

Patient & Prescribing Data

Patients being evaluated for suspected tuberculosis or nontuberculous mycobacterial infection; the article highlights suspected mixed infections and immunocompromised patients.

The article provides no prescribing regimen. It states that earlier species-level identification could support more timely treatment decisions, while emphasizing that molecular results must be interpreted with clinical findings.